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Abstract
Background: Mass drug administration of praziquantel is the World Health Organization’s endorsed control strategy
for schistosomiasis. A decade of annual treatments across sub-Saharan Africa has resulted in significant reductions of
infection prevalence and intensity levels, although ‘hotspots’ remain. Repeated drug treatments place strong selective
pressures on parasites, which may affect life-history traits that impact transmission dynamics. Understanding drug
treatment responses and the evolution of such traits can help inform on how to minimise the risk of drug resistance
developing, maximise sustainable control programme success, and improve diagnostic protocols.
Methods: We performed a four-generation Schistosoma mansoni praziquantel selection experiment in mice and snails.
We used three S. mansoni lines: a praziquantel-resistant isolate (R), a praziquantel-susceptible isolate (S), and a co-
infected line (RS), under three treatment regimens: untreated, 25 mg/kg praziquantel, or 50 mg/kg praziquantel. Life-
history traits, including parasite adult-worm establishment, survival, reproduction (fecundity), and associated morbidity,
were recorded in mice across all four generations. Predictor variables were tested in a series of generalized linear mixed
effects models to determine which factors had a significant influence on parasite life-history traits in definitive hosts
under different selection regimes.
Results: Praziquantel pressure significantly reduced adult-worm burdens across all generations and isolates, including
within R-lines. However, previous drug treatment resulted in an increase in adult-worm establishment with increasing
generation from P1 to F3. The highest worm numbers were in the co-infected RS line. Praziquantel treatment
decreased adult-worm burden, but had a larger negative impact on the mean daily number of miracidia, a proxy for
fecundity, across all three parasite isolates.
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Conclusions: Our predicted cost of resistance was not supported by the traits we measured within the murine host.
We did not find evidence for negative adult worm density-dependent effects on fecundity. In contrast, of the adult
worms that survived treatment, even low doses of praziquantel significantly reduced adult-worm fecundity. Such
reductions in worm fecundity post treatment suggest that egg - based measures of drug efficacy, such as Kato-Katz,
may overestimate the short-term effect of praziquantel on adult - worm burdens. These findings have important
implications for S. mansoni transmission control, diagnostic protocols, and the potential for undetected selection
toward drug resistance.
Keywords: Schistosoma mansoni, Biomphalaria, Mouse, Praziquantel, Resistance, Establishment, Survival, Fecundity,
Trade-offs
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Background
Schistosomiasis is an infectious disease of poverty. The
causative agents are platyhelminths of the class Trema-
toda. The majority of human intestinal schistosomiasis
infections are caused by Schistosoma mansoni, a species
found predominantly in Africa and South America. Eggs
of S. mansoni are excreted in the stool. When faeces
contaminate freshwater water through poor or lack of
sanitation, the eggs hatch into miracidia. These miracidia
infect Biomphalaria snail species where they reproduce
asexually to produce cercariae. These cercariae are dir-
ectly infective to humans; people are exposed when they
contact infected water sources when bathing, swimming,
fishing, and doing other water-based activities.
Schistosoma mansoni infection commonly causes an-
aemia, abdominal pain, and reduced physical and cog-
nitive development. In up to 200,000 people per year,
more severe chronic infections lead to complications
such as hepatomegaly, splenomegaly, hepatic fibrosis,
and/or cancer – leading to death in up to 20,000
people per year [1]. Morbidity from Schistosoma spp.
infection is mainly caused by the density of eggs in the tis-
sues, rather than adult worm numbers [2]. Schistosomiasis
is second only to malaria in terms of its global parasitic
morbidity and mortality burden and socioeconomic
importance [3].
Over 230 million people are infected with schistosomiasis
[4], with over 90% of these living in sub-Saharan Africa [5].
Efforts to improve water, sanitation, and hygiene facil-
ities (WASH), as well as the control of snail popula-
tions, have been used to reduce transmission [6, 7].
However, the primary strategy currently endorsed by
the World Health Organization (WHO) for lowering
schistosomiasis burden and associated morbidity is
Preventive Chemotherapy (PC) using praziquantel mass
drug administration (MDA) [8, 9].
Low costs and large public-private partnership do-
nations enable praziquantel’s use [10, 11] and over 52
countries have adopted this MDA strategy. In 2015,
66.5 million individuals worldwide received a MDA
treatment for schistosomiasis, 81% of whom were
school-aged children, and 87% were in Africa [12].
However, for S. mansoni the WHO endorsed 40 mg/
kg praziquantel treatment has a parasitological cure
rate of between 52 and 92% [13], with lower cure
rates and egg reduction rates seen in areas which
have received multiple annual treatments [14]. Under-
dosing due to low drug absorption of the 40 mg/kg
may also lead to even lower efficacy than previously
thought, particularly in children due to pharmacoki-
netic factors [15, 16].
Annual MDA targeted at school-aged children has
however been, in general, highly successful in reducing
morbidity, prevalence and intensity in several regions,
covering a range of baseline profiles [17–20]. This led the
WHO to update their strategy in 2013 from morbidity
control to elimination as a public-health problem [1, 9].
Nethertheless, some regions have reported little to no
change in infection prevalence or intensity [14]. Monitor-
ing the outcomes of MDA on intestinal schistosomiasis
commonly involves parasitological examination of stool
using Kato-Katz smears to confirm the presence of eggs,
which are used as a proxy for adult worm numbers [21].
In areas where MDA has been successful, eggs are present
in fewer individuals and/or the egg counts (representative
of the intensity of infection) are lower. In areas where
MDA has been less successful: egg counts can tempor-
arily decline but there is little to no change in the num-
ber of people infected nor the long term mean infection
intensities [14, 22]. The more sensitive point-of-care
circulating cathodic antigen test (POC CCA) detects anti-
gens from adult worms in active infections [23, 24]. POC
CCAs show significantly lower cure rates than the Kato-
Katz, and indicates that the positive linear association be-
tween adult worms and eggs might not hold post treat-
ment [22]. This potentially indicates drug-induced
embryostasis (the temporary or permanent cessation of
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egg production) as seen in onchocerciasis [25] and ascar-
iasis [26].
Repeated drug treatments in the laboratory can lead to
drug resistance developing [27, 28], with sporadic
evidence of reduced treatment success in S. mansoni en-
demic communities [14, 29–32]. However, drug resistance
is commonly associated with life-history costs such as
reduced infectivity, survival and/or reproduction in hel-
minths and other infectious agents [33–35]. Such costs
are not only limited to drug resistance, but host-parasite
trade-offs can occur throughout the life-cycle [36–41]. In
areas where annual praziquantel treatment is ineffective at
reducing the burden of schistosomiasis, it is important to
pinpoint potential reasons underlying the failure of
control strategies and these are likely to be affected by
host-parasite-drug interactions and associated trade-offs.
We tested the prediction that S. mansoni exposed
to multiple doses of praziquantel across multiple genera-
tions would display fitness costs, which could subse-
quently slow the spread or establishment of resistance in
natural settings. We used a four generation S. mansoni
selection study in laboratory mice and Biomphalaria
snails to quantify the effects of in vivo praziquantel
treatment on adult - worm establishment, survival, and
fecundity. We compared praziquantel-susceptible and
praziquantel-resistant parasite lines and the effects of
varying levels of in vivo praziquantel exposure. We also
predicted that with reduced intra-host competition post
treatment due to lower worm numbers, we would see a
relaxation of density dependence on adult - worm
reproduction levels. The aim of the experimental selec-
tion study was to better understand the effect of long-
term MDA, the associated risks of drug resistance devel-
oping and spreading, and other potential life-history ef-
fects of repeated mass treatments.
Methods
Details of host and parasites
Parasites
Two populations of S. mansoni isolates, originally ob-
tained from infected people in Egypt in 1996 and subse-
quently undergoing multiple passages in the laboratory,
were used to test the differences between susceptible and
resistant parasite isolates. The putatively praziquantel-
susceptible MOC isolate (henceforth S) was established
from eggs excreted by a person living in the Nile region in
Egypt prior to receiving a single 40 mg/kg praziquantel
treatment that resulted in successful clearance of the para-
site measured by Kato-Katz [42]. The parasite line has a
mean ± standard deviation (SD) praziquantel ED50 of
80.0 ± 15 mg/kg in laboratory mice [43]. The second para-
site isolate used in our experiment was EE2, an isolate
established from eggs excreted by a person living in the
Nile region in Egypt prior to three non-curative
praziquantel treatments of 40 mg/kg, 40 mg/kg and then
60 mg/kg, respectively [42]. The resultant parasite line has
a mean ± SD praziquantel ED50 of 212 ± 86 mg/kg in
laboratory mice [43] and this isolate will be referred to as
R for the remainder of the manuscript. The third parasite
line was a mixed genotype infection with R and S
(referred to as RS).
Definitive hosts
To reduce the influence of mice age, sex, and weight on
the infectivity and development of cercariae, schistoso-
mula, and adult worms [44], only female Tuc Ordinary
(TO) Harlan® mice were infected, 7 days post arrival at
the facility when they all weighed between 16 and 20 g.
Mice were fed ad libitum on a uniform sterile diet of
Clark’s Rat and Mouse food (CRM) (Lillico Ltd., UK).
The mice paddled freely for 30 min in 100 ml of spring
water containing the cercarial dose as described in detail
in ‘Experimental design’ below.
Intermediate hosts
Laboratory snail lines of Biomphalaria glabrata and B.
alexandrina were used to passage R, S, and RS. A
laboratory strain of B. glabrata, (#2 strain) known to be
highly susceptible to S. mansoni infection and laboratory
mixed genotype B. alexandrina were used to reduce bot-
tlenecking effects by increasing molluscan host hetero-
geneity [45, 46]. All snails were maintained at 24–25 °C
and subjected to a light regime of 11 h light, 1 h dusk,
11 h dark and 1 h dawn [39, 47]. Individual snails were
housed in individual plastic pots (10 cm × 8 cm × 5 cm)
in 100 ml spring water (Iceland Ltd), changed weekly,
and were provided with Styrofoam sheets where they
preferentially deposit their eggs [48]. All snails were fed
ad libitum on iceberg lettuce. All snails were maintained
in isolation for a minimum of 1 week prior to miracidia
exposure - this allowed acclimatization to individual
conditions and differential auto- and allo-sperm storage
[49, 50]. All snails were size-matched between treatment
groups with a mean ± SD size of 10.19 ± 0.05 mm.
Experimental design
Generation 1 (P1): Nine groups of four adult mice were
exposed to 220 cercariae, a dose which had previously
demonstrate high likelihood of infection with minimal
unnecessary pathology in the mouse model, [39] of one
of the three S. mansoni parasite lines: R, S, or RS (110
cercariae from each of S and R). These cercariae were
pooled from snails 70 days post snail exposure to mira-
cidia. Maturity of adult S. mansoni worms and subse-
quent egg production in mice takes approximately
42 days [51] and juvenile worms are not susceptible to
praziquantel treatment. 42 days post-cercariae exposure,
all mice were weighed, ear marked, and treated by oral
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gavage with 1) a sham 2% cremophor EL (control) dose, 2)
a sub-curative low dose of 25 mg/kg praziquantel in 2%
cremophor EL, or 3) a sub-curative medium dose of
50 mg/kg praziquantel in 2% cremophor EL (Fig. 1).
Infected animals were euthanised 47 to 62 days post-
cercariae exposure, using the schedule 1 method of cervical
dislocation. Mice were euthanised prior to clinical morbid-
ity, but post adult worm establishment, sexual maturity,
and commencement of egg production. Adult schisto-
somes were recovered by a modified hepatic perfusion
technique [52] and the worms were scored as paired or
single, counted, sexed, and a subset’s length was measured
(up to 10 of each of the paired, unpaired, male and female
combinations). Weight of each mouse liver, spleen, and
total body were recorded to the nearest mg.
The liver and spleen from each mouse were used to
obtain eggs for hatching. These tissues of each mouse
were macerated through a sieve in 250 ml 0.85% sa-
line, left to sediment for 10 minutes, 200 ml super-
natant was then removed and replaced with 200 ml
saline. This was left to stand for a further 10 minutes
and then the top 240 ml supernatant removed. The
remaining sediment was washed out with 70 ml
spring water and placed in direct light for 1 hour.
Miracidia numbers, hatched from the eggs obtained
from each mouse, were estimated in ten 0.2 ml sam-
ples per mouse.
Miracidia obtained from each of the four mice per
experimental group were pooled and then used to infect
30 B. glabrata and 20 B. alexandrina snails per experi-
mental line. Snails were individually exposed to six
miracidia for 2 hours in 5 ml spring water. At 10 weeks
post-miracidia exposure, the snails were kept in the dark
for 24 h and then exposed to light to induce shedding of
cercariae. Cercariae were pooled from ten snails per
treatment group (including any B. alexandrina where
possible).
Generation 2 (F1): 110 pooled cercariae from P1 snails
were then used to infect four mice per experimental line.
This dose was half that of the original P1 dose of 220
cercariae, due to unnecessary morbidity observed in the
first generation. In addition to the original nine treatment
groups, four extra mice served as untreated controls for
each parasite line that had received praziquantel in the
previous generation (Fig. 1). This enabled life-history traits
of the parasite genotypes to be observed independently of
a subsequent praziquantel dose, such as adult worm
establishment and fecundity. These mice are termed
Control2 mice. This protocol was continued until the
fourth generation (F3) of mice.
Measurements recorded at culling are described above
and include: (i) weight of mouse body, liver and spleen; (ii)
virulence proxy (liver and spleen as a proportion of total
weight) [53]; (iii) number of worms with details on paired
status, sex and length (subset); and (iv) mean number of
miracidia obtained from the liver and spleen of each
mouse 1 hour after hatching (proxy for fecundity).
Statistical analyses
Parasite life-history traits were modelled as outcome
variables using generalized linear mixed effects models
(GLMMs). The focus for the analysis was on adult estab-
lishment (number of adult worms), average daily worm
pair miracidial output (hatched eggs), and host virulence
(proportion of mouse weight that is spleen and liver).
Adult establishment and miracidial output were modelled
with the nbinom1 family and logit link function using the
‘glmmadmb’ function in the package glmmADMB (http://
glmmadmb.r-forge.r-project.org/). Virulence data were log
transformed and analysed using a Gaussian distribution
with lmer in lme4 package [54]. In all models, treatment
group was included as a random effect. Predictor variables
included: (i) experimental treatments (parasite line, prazi-
quantel dose, praziquantel selection line (praziquantel
Fig. 1 Experimental design for longitudinal selection of Schistosoma mansoni under in vivo praziquantel pressure (0, 25, or 50 mg/kg) for three
parasite lines (susceptible (S), resistant (R), and a coinfected line (RS)). Praziquantel treatment was administered to the mice 42 days after parasite
exposure. Mice were culled between days 47 and 62. Resultant miracidia were used to infect the snail at 6 miracidia/snail. In P1 mice were
infected with 220 cercariae/mouse. For F1-F3, 110 cercariae/mouse were used. The experimental design shown here is an example showing only
the parasite line started with the S isolate
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dose in current or previous generation), laboratory gener-
ation); (ii) definitive host variables (weight at treatment,
weight at cull, percentage change in mouse weight, num-
ber of days post treatment for culling); and (iii) parasite
characteristics (length of worms (paired, unpaired, male,
female)). Model selection was performed in a stepwise
manner, using Akaike information criterion (AIC) to
compare between models of different complexities. Final
models were checked for overdispersion. For models that
used a negative binomial distribution, estimates were
converted to incidence rate ratios (IRR) to improve inter-
pretation and 95% confidence intervals were calculated.
Results
Worm establishment and survival
Adult worm numbers were measured between days 47–62
post infection, equating to 5–20 days post praziquantel
treatment (mean = 9.9 days). Although cull day post treat-
ment affected the establishment and survival of adult
worms in a univariate model (IRR: 0.96; 95% CI: 0.94,
0.99), it was not significant once included in multivariate
models or present as a predictor in the best fit model.
Because different cercarial doses were used between P1
(220 cercariae/mouse) and F1-F3 (110 cercariae/mouse),
the number of adult worms was standardized to com-
pare between generations. The total number of worms
measured integrates both the establishment and sur-
vival of adult worms to the cull date and hence we were
unable to distinguish between these two processes in this
analysis of the mice.
The best-fit model to explain standardized adult worm
abundance included parasite line, praziquantel selection
in current or previous generation, the percentage weight
change between treatment and culling, and generation
(Table 1). Adult worm numbers were highest in the RS
line (IRR: 1.33, 95% CI: 1.15, 1.53) compared to S line,
but there was no significant difference between R and S
lines (IRR:1.05, 95% CI:0.91, 1.23). Praziquantel selection
from treatment in the current generation, successfully
decreased adult worm numbers in both the low (IRR:
0.83, 95% CI: 0.71, 0.97) and medium (IRR: 0.80; 95% CI:
0.68, 0.94) praziquantel dose groups. Greater weight loss
after treatment was associated with a reduction in worm
abundance (IRR: 0.17; 95% CI: 0.083, 0.33). However, in
each generation, overall worm establishment and/or
survival (being unable to differentiate these) increased
(IRR: 1.26, 95% CI: 1.19,1.34).
Adult worm sex ratios and sizes
Throughout the experiment, unpaired females were
rarely found. The sex ratio (number of females: number
of males) was often below 1, meaning an excess of un-
paired males. For parasite lines that were exposed to the
consistent praziquantel selection pressure throughout all
four generations (Fig. 2, Control2s are not shown), there
was an increase in the female: male ratio with increasing
generation, and within parasite lines as the praziquantel
dose increased. In P1, more female worms survived the
50 mg/kg treatment than males in all three parasite
lines, with the greatest difference in S. This trend was
not seen again in any of the three subsequent treated
Table 1 The estimates for each of the predictor variables included in the best-fit multivariate generalized linear mixed models
(GLMMs) for the standardized total number of adult Schistosoma mansoni adult worms and daily miracidia per worm pair
Variable Number of adult worms Daily hatched miracidia per pair
IRR (95% CI) IRR (95% CI)
Intercept 14.56*** 21.53***
(11.11, 19.08) (18.20, 25.47)
Parasite line (baseline: S)
R 1.06 (0.91, 1.23) 0.95 (0.76, 1.18)
RS 1.33*** (1.15, 1.53) 1.21 (0.98, 1.50)
Praziquantel selection (baseline: control)
Low selection 0.83* (0.71, 0.97) –
High selection 0.80** (0.68, 0.94) –
Praziquantel treatment (baseline: 0 mg/kg)
25 mg/kg – 0.37*** (0.29, 0.47)
50 mg/kg – 0.26*** (0.20, 0.33)
Generation 1.26*** (1.19, 1.34) –
Proportion weight change 0.17*** (0.08, 0.33) –
IRR incidence rate ratio, CI confidence interval, * P < 0.05, **P < 0.01, ***P < 0.001
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generations. We also measured the length of adult
worms to determine if the size of worms affected their
ability to persist and produce eggs after praziquantel
treatment. There were no significant differences between
parasite lines or praziquantel treatment groups in worm
size (unpaired males, paired males, unpaired females,
and paired females or overall) and worm size was not a
significant predictor of worm establishment or fecundity
(Additional file 2: Figure S1).
Daily worm fecundity
Fecundity of worm pairs was measured by hatching eggs
recovered from the spleen and liver of mice. As samples
were not all collected on the same day across all experi-
mental groups, in order to standardize rates, total mira-
cidia estimates were divided by days post-treatment and
the number of worm pairs. The best-fit model for fe-
cundity included praziquantel dose and parasite isolate
(Table 1). Treatment with praziquantel was associated
with a significantly lower fecundity (low praziquantel
IRR: 0.37, medium praziquantel IRR: 0.24) compared
with control mice (Fig. 3). There was no significant dif-
ference between parasite lines: RS had a non-significant
slightly higher (IRR = 1.21, 95% CI: 0.98, 1.50) fecundity
compared to the S line, whereas R was not different
(IRR = 0.95, 95% CI: 0.76, 1.18) from S. Although differ-
ences in parasite line effects were not significant individu-
ally, including parasite line in the model significantly
improved the fit. We did not find support for density-
dependent effects on fecundity: viable miracidia production
per worm was not significantly linked to either worm pair
numbers or total worm burden (Additional file 2: Figure S2).
Morbidity of definitive hosts
Virulence of parasites in definitive hosts was estimated
using the proportion of a mouse’s body weight that was
liver and spleen. This standard metric reflects not only
the immunogenic eggs released by adult worms, but also
inflammation and immunopathology induced during in-
fection [2]. Virulence in a mouse significantly increased
with the logarithm of the number of miracidia recorded
(estimate = 1.22, SE = 0.42, Table 2). Praziquantel treat-
ment was positively associated with higher virulence, but
the lower praziquantel dose had a larger effect (2.11,
SE = 0.43) than the higher dose (1.54, SE = 0.46). As the
relative size of the liver and spleen was used as a viru-
lence proxy and measurements were taken before eggs
were removed, we checked to assess if this was a
Fig. 2 Sex ratios of Schistosoma mansoni adult worms across four generations for each parasite line and praziquantel treatment regime. Each
panel of the figure represents one of the four generations labelled from 1 (P1) through to 4 (F3). Values above 1 indicate an excess of females,
whilst values below 1 indicate an excess of males
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confounding variable. However, total miracidia was not
related to virulence in a predictable manner (Additional
file 2: Figure S3). Although alternative models were fit
without total miracidia, none were as parsimonious as
the model only including praziquantel dose and
miracidia numbers.
Discussion
We characterized, within a laboratory experimental set-
ting, adult - worm establishment, fecundity, and viru-
lence of praziquantel-susceptible and praziquantel-
resistant S. mansoni lines in their (murine) definitive
hosts, under in vivo praziquantel pressure and in un-
treated groups. In vivo praziquantel treatment signifi-
cantly reduced fecundity in surviving adult worms, but
with no significant difference between parasite lines.
Daily fecundity per worm pair was negatively associated
with in vivo praziquantel concentration. This reduction
in fecundity with treatment has important implications
for control programs and the monitoring of S. mansoni
drug efficacy using egg based diagnostics alone.
In endemic communities, parasitological examination of
the stool, most commonly the Kato-Katz thick smear tech-
nique [21], is used to evaluate praziquantel efficacy [55].
Improved statistical analyses help to accurately character-
ise egg reduction rates [56, 57] and the effects of multiple
MDA rounds [14]. However, Kato-Katzs have poor sensi-
tivity at low infection intensities and post treatment [22,
58, 59]. If adult worms survive treatment, but have a lower
fecundity, then Kato-Katzs and other egg based diagnostic
methods may further indicate a greater reduction in worm
burden (infection intensity, measured as egg per gram of
stool are taken as a proxy for adult worm numbers) than
has actually occurred.
Our laboratory findings here strongly support field
based research where, for example, adult worm antigen
diagnostics (POC CCA) demonstrated significantly lower
cure rates than Kato-Katzs, which were unlikely to be
explained by diagnostic sensitivity alone [22]. From our
field results we could not differentiate between adult
worms surviving treatment but with a cessation of egg
production (embryostasis) from juvenile worm infections
that had not yet become egg patent [22]. If praziquantel
induces a degree of embryostasis, and this is permanent,
Table 2 The estimates for predictor variables from the best fit
linear mixed model for virulence associated with Schistosoma
mansoni infection in mice
Predictor Variables Virulence percentage of weight
that is liver and spleen
Est (SE)
Intercept 4.7** (1.43)
Praziquantel treatment (baseline: 0 mg/kg)
25 mg/kg 2.11*** (0.43)
50 mg/kg 1.54** (0.46)
log10 (total miracidia) 1.22** (0.42)
SE standard error; * P < 0.05, **P < 0.01, ***P < 0.001
Fig. 3 Daily mean viable Schistosoma mansoni miracidia output per worm pair (fecundity). Each boxplot summarizes the daily miracidial output
per pair across four generations for each parasite line and praziquantel treatment dose
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or semi-permanent, then from a virulence standpoint this
will result in lower egg numbers and therefore lower asso-
ciated morbidity and transmission [2] even though the
mechanism involved will be different to that of worm
death. However, if such embryostasis is only temporary,
then it could have far greater implications, and be a form
of drug resistance that would contribute to the future
genepool whilst being undetected by standard egg diag-
nostic methods. This in turn may even result in fecundity
compensation when egg production is reinstated, that
could be detected by genetic analyses of offspring, where
intensities are similar to pre-treatment levels, but from a
smaller effective breeding population (Gower et al., in
preparation). This highlights the importance of studies
such as ours in understanding the complex effects of drug
treatment and selection.
Our field and laboratory studies to date cannot confirm
if this potential embryostasis is permanent or temporary,
but genetic studies of the miracidia offspring using sibship
analyses to infer parental genotypes could inform if future
eggs are from new or surviving worms. Such a drug in-
duced reduction in fecundity, without death or damage to
the adult worms, has been reported for schistosomes
using nicarbazin [60], but not previously reported for
praziquantel. Such potential embryostasis is further sup-
ported by a link between an agent (United States Patent
6,514,963) that inhibits egg production in schistosomes
and also inhibits the influx of calcium through cell mem-
brane channels, which are thought to be associated with
the action of praziquantel [61].
One limitation of our study is that the effect of prazi-
quantel directly on schistosome eggs is not completely
understood, and what we report as a reduction in fecund-
ity, measured here as daily miracidia per worm pair, could
be an artefact of eggs becoming non-viable with prazi-
quantel treatment [62] and we could be underestimating
the daily egg production per worm pair. In contrast, if egg
production had begun several days before we treated with
praziquantel, then we would be overestimating fecundity.
In addition to the fecundity reductions discussed above,
praziquantel treatment also reduced adult - worm sur-
vival, in particular lowering the number of male worms
seen as an increase in the female to male worm ratio (Fig.
2). This finding supports studies reporting higher survival
in females following praziquantel treatment [63, 64], po-
tentially due to the location of females, being physically
protected by males in their gynecophoric canal and there-
fore less susceptible to praziquantel [65]. This was particu-
larly apparent in the first generation (P1), where S had a
rare surplus of females after the 50 mg/kg praziquantel
treatment dose. Changes in sex ratio with treatment could
also impact host morbidity, reproductive success of the
parasite and could have implications for future adaptation.
For example, with an imbalanced sex ratio, mate swapping
[66] could increase parasite heterogeneity without increas-
ing overall egg numbers, particularly with males capable
of mating with multiple females [67]. Such mate swapping
cannot be detected in humans by standard parasitological
techniques but could be detected by population genetic
approaches. Such increased outbreeding in schistosomes
has been previously demonstrated through resistance
selected snails in the laboratory [40]. Although sex sensi-
tivity can also vary by strain [62] we did not observe any
significant differences between parasite lines, potentially
due to the sub-curative doses we were administrating,
which were imposed to increase selective pressure for
potential drug resistance.
Previous laboratory studies have shown both the loss of
resistance in the absence of praziquantel exposure [68]
and the gain of resistance phenotypes in susceptible lines
under selection in as few as six laboratory generations
[27]. In our selection study parasite line was a better pre-
dictor of selection, in this instance worm establishment,
than in vivo praziquantel dose. For example, the S line
that had been exposed to high praziquantel doses in previ-
ous generations, but not in the current generation, had in-
distinguishable adult - worm establishment and survival
from those which continued to receive praziquantel
treatment.
Although R had higher adult survival compared with
S, there was not a significant difference between fecund-
ity and virulence (when unexposed to praziquantel). RS,
on the other hand, had significantly higher adult worm
numbers and higher fecundity. This may be due to out-
breeding of two potentially inbred laboratory lines, ra-
ther than innate fitness benefits. The S and R isolates
had been maintained in the laboratory for many genera-
tions and are likely to have undergone a population
bottleneck [69]. We also observed higher adult - worm
establishment per cercaria with increasing generation. A
potential explanation for this is that the initial worm ex-
posure burdens were higher due to larger cercarial ex-
posure (220 cercariae vs. 110 cercariae in subsequent
generations) and subsequent density - dependent effects
may have limited adult establishment in P1.
Morbidity from Schistosoma infections is mainly
caused by the density of eggs in the tissues, rather than
the presence of the adult worms [2]. In this study, viru-
lence was best predicted by dose of praziquantel and
total egg burden. In humans, the severity of schistosom-
iasis symptoms is related to infection intensity [70], host
immune response [71] and parasite genotype [72]. Here
we observed no significant difference between morbidity
indicators and parasite line, eluding to the fact that if
drug resistance develops, associated morbidity should
not worsen.
Here we show that a reduction in fecundity, most
significantly affected by praziquantel treatment, has
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positive benefits for murine hosts in the short term. In
contrast, praziquantel treatments increased our viru-
lence estimates. As praziquantel works synergistically
with the immune system [73–75] and the spleen is asso-
ciated with the production of white blood cells, then a
possible explanation for the increase in spleen weight
with treatment could be the effect of praziquantel acting
in conjunction with the immune system. This is further
supported by field observations in Burundi, where prazi-
quantel treatment successfully reduced periportal fibro-
sis and hepatomegaly but was associated with an
increase in splenomegaly up to 2 years after treatment
with praziquantel [76]. Also, in Sudan the percentage of
patients with hepatomegaly decreased significantly up to
2 years after praziquantel treatment but splenomegaly
remained unchanged [77]. Correlations between S. man-
soni infection intensity and morbidity are not clearly
delineated and may be altered with chemotherapy. Our
study highlights the complexity of co-examining morbid-
ity and changes in infectious status and intensities, and
supports potential independent evaluation of such mea-
sures in community based control programmes [78].
Previous studies have demonstrated weak costs of
schistosome resistance to praziquantel in the definitive
mouse host, or indeed benefits, to be often mirrored by
greater costs in the molluscan host [68]. We did not
observe life-history costs associated with praziquantel
resistance in murine hosts. Indeed, traits associated with
R were higher worm numbers in the definitive mouse
host, however this may be intrinsically linked to
greater negative trade-off traits in intermediate snail
hosts [79, 80]. Transmission of schistosomiasis is reli-
ant on the fitness of the parasite in both the definitive
and intermediate hosts. Schistosomes can be highly
virulent to their snail hosts, raising mortality rates and
reducing host reproduction by exploiting reproductive
tissues [36, 37, 39, 79, 81, 82]. Investigations into the
molluscan life-cycle stages of these parasite lines as
selection occurs will help evaluate whether the prazi-
quantel selective pressures are propagated through the
next stage of the life cycle.
Our study used S. mansoni parasite lines and although
it is likely that other schistosome species may behave
similarly, this cannot be substantiated without further
research. Additional studies using a more diverse range
of susceptible and resistance parasite lines (S. mansoni
and other spp.) would help to support any differences
observed here.
Conclusion
This study has highlighted a significant decrease in fe-
cundity in both praziquantel-susceptible and praziquantel-
resistant S. mansoni lines with treatment. The effect of
praziquantel had a larger impact on fecundity than adult
worm survival. This has important public health implica-
tions for monitoring drug efficacy in control programs, as
standard egg based diagnostics, such as Kato-Katz may
over estimate drug efficacy in comparison to adult worm
antigen detecting methods, such as POC CCA. Our find-
ings also demonstrated that drug resistance was not asso-
ciated with significant life-history costs in the murine
host. This could indicate that if drug resistance is selected
for in the field it may be more likely to spread, potentially
without being detected. However further work on poten-
tial costs in the snail hosts are warranted, as well as
genetic studies on parasites being excreted post treatment
to establish if S. mansoni embryostasis occurs in treated
humans, and if so, if the worms go on to contribute these
potential resistant parasites into the gene pool or if egg
cessation is permanent.
Additional files
Additional file 1: Lamberton et al. 2017 IDoP Multilingual abstracts in
the five official working languages of the United Nations. (PDF 861 kb)
Additional file 2: Lamberton et al. 2017 IDoP Supplementary Figures 1,
2 and 3. (DOCX 322 kb)
Additional file 3: Lamberton et al. 2017 IDoP Raw mouse and worm
data from experimental infections. (XLSX 242 KB)
Abbreviations
AIC: Akaike information criterion; CI: Confidence interval; GLMM: Generalized
linear mixed models; IRR: Incidence rate ratio; MDA: Mass drug
administration; PC: Preventative Chemotherapy; POC CCA: Point-of-care
circulating cathodic antigen test; SD: Standard deviation; WHO: World Health
Organization; WASH: Water, Sanitation, and Hygiene
Acknowledgements
We would like to thank Mike Anderson and Fiona Allan at the Natural
History Museum, London and Chris, Chris, Tessa, Mark and Steve at the CBS
unit, Imperial College London for assistance with the snail maintenance and
some of the weekly snail measurements. We are indebted to Mike Doenhoff
from the Universities of Bangor and Nottingham and Mike Anderson from
the Natural History Museum, London for the snail lines.
Funding
PHLL and CLF are currently funded by PHLL’s European Research Council
Starting Grant [680,088 SCHISTO_PERSIST], and PHLL is also funded by a
Wellcome Trust ISSF Grant [105,614/Z/14/Z] and a Lord Kelvin Adam Smith
Leadership Fellowship. JPW’S current Schistosoma research is funded by a
ZELS research grant (combined BBSRC, MRC, ESRC, NERC, DSTL & DFID: BB/
L018985/1), a BBSRC Impact Accelerator Grant (BB/GCRF-IAA/19), and a
SCORE research grant (The University of Georgia Research Foundation,
funded by the Bill and Melinda Gates Foundation: RR374–053/4785426).
During the experiment study PHLL was funded by a Medical Research
Council PhD studentship and JPW was funded by a Royal Society University
Research Fellowship. Funding for the laboratory facilities was given from
the Schistosomiasis Control Initiative.
Availability of data and materials
Data included in statistical analysis are provided in Additional file 3
Authors’ contributions
PHLL and JPW designed the project, PHLL undertook the experiments, PHLL
and CLF performed the analyses, PHLL CLF and JPW wrote the manuscript.
All authors read and approved the final manuscript.
Lamberton et al. Infectious Diseases of Poverty  (2017) 6:110 Page 9 of 11
Competing interests
The authors declare that they have no competing interests.
Consent for publication
All authors approved the manuscript for publication.
Ethics approval and consent to participate
The work was performed under Home Office project licenses PPL 30/2032
and PPL 30/1805, and all procedures were classed as ‘mild’.
Author details
1Institute for Biodiversity, Animal Health, and Comparative Medicine &
Wellcome Centre for Molecular Parasitology, College of Medical, Veterinary &
Life Sciences, University of Glasgow, G12 8QQ, Glasgow, UK. 2London Centre
for Neglected Tropical Disease Research, Department of Infectious Disease
Epidemiology, School of Public Health, Imperial College London, St Mary’s
Campus, W2 1PG, London, UK. 3Centre for Endemic, Emerging and Exotic
Diseases, The Royal Veterinary College, University of London, London AL9
7TA, UK.
Received: 9 February 2017 Accepted: 6 June 2017
References
1. WHO. Schistosomiasis. Progress report 2001–2011 and strategic plan 2012–
2020. Geneva: World Health Organization; 2013. http://www.who.int/iris/
bitstream/10665/78074/1/9789241503174_eng.pdf. Accessed: 30 Mar 2017
2. Boros DL. Immunopathology of Schistosoma mansoni infection. Clin
Microbiol Rev. 1989;2(3):250–69.
3. Fenwick A, Webster JP, Bosque-Oliva E, Blair L, Fleming FM, Zhang Y, et al.
The Schistosomiasis control initiative (SCI): rationale, development and
implementation from 2002-2008. Parasitology. 2009;136(13):1719–30.
4. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet.
2014;383(9936):2253–64.
5. WHO. Investing to overcome the global impact of neglected tropical
diseases. Third WHO report on neglected tropical diseases. Geneva: World
Health Organization; 2015. http://www.who.int/neglected_diseases/
9789241564861/en/ Accessed 30 Mar 2017
6. Grimes JE, Croll D, Harrison WE, Utzinger J, Freeman MC, Templeton MR.
The roles of water, sanitation and hygiene in reducing schistosomiasis: a
review. Parasit Vectors. 2015;8:156.
7. King CH, Sutherland LJ, Bertsch D. Systematic review and meta-analysis
of the impact of chemical-based mollusciciding for control of
Schistosoma mansoni and S. haematobium transmission. PLoS
Negl Trop Dis. 2015;9(12):e0004290.
8. WHO. Preventative chemotherapy in human helminthiasis: coordinated use
of anthelminthic drugs in control interventions: a manual for health
professionals and programme managers. Geneva: World Health
Organization; 2006. http://whqlibdoc.who.int/publications/2006/
9241547103_eng.pdf. Accessed: 30 Mar 2017
9. Webster JP, Molyneux D, Hotez P, Fenwick A. The contribution of mass drug
administration to global health – past, present and future. Philos Trans R
Soc Lond Ser B Biol Sci. 2014;369(1645):1471–2970.
10. Fenwick A, Savioli L, Engels D, Bergquist NR, Todd MH. Drugs for the control
of parasitic diseases: current status and development in schistosomiasis.
Trends Parasitol. 2003;19(11):509–15.
11. Molyneux DH, Malecela MN. Neglected tropical diseases and the
millennium development goals: why the “other diseases” matter: reality
versus rhetoric. Parasit Vectors. 2011;4:234.
12. WHO. Schistosomiasis and soil- transmitted helminthiases: number of
people treated in 2015. Wkly Epidemiol Rec. 2016;91(49):585–600.
13. Danso-Appiah A, Olliaro PL, Donegan S, Sinclair D, Utzinger J. Drugs for
treating Schistosoma mansoni infection. Cochrane Database Syst Rev.
2013;2:CD000528.
14. Crellen T, Walker M, Lamberton PH, Kabatereine NB, Tukahebwa EM, Cotton
JA, et al. Reduced efficacy of praziquantel against Schistosoma mansoni is
associated with multiple rounds of mass drug administration. Clin Infect Dis.
2016;63(9):1151–9.
15. Olliaro P, Delgado-Romero P, Keiser J. The little we know about the
pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-
enantiomer). J Antimicrob Chemother. 2014;69(4):863–70.
16. Bustinduy AL, Waterhouse D, de Sousa-Figueiredo JC, Roberts SA, Atuhaire
A, Van Dam GJ, et al. Population pharmacokinetics and pharmacodynamics
of praziquantel in Ugandan children with intestinal Schistosomiasis: higher
dosages are required for maximal efficacy. MBio. 2016;7(4):e00227.
17. Kabatereine NB, Brooker S, Koukounari A, Kazibwe F, Tukahebwa EM,
Fleming FM, et al. Impact of a national helminth control programme on
infection and morbidity in Ugandan schoolchildren. Bull World Health
Organ. 2007;85(2):91–9.
18. Toure S, Zhang Y, Bosque-Oliva E, Ky C, Ouedraogo A, Koukounari A, et al.
Two-year impact of single praziquantel treatment on infection in the
national control programme on schistosomiasis in Burkina Faso. Bull World
Health Organ. 2008;86(10):780–7.
19. French MD, Churcher TS, Gambhir M, Fenwick A, Webster JP, Kabatereine
NB, et al. Observed reductions in Schistosoma mansoni transmission from
large-scale administration of praziquantel in Uganda: a mathematical
modelling study. PLoS Negl Trop Dis. 2010;4(11):e897.
20. Hodges MH, Dada N, Warmsley A, Paye J, Bangura MM, Nyorkor E, et al.
Mass drug administration significantly reduces infection of Schistosoma
mansoni and hookworm in school children in the national control program
in Sierra Leone. BMC Infect Dis. 2012;12:16.
21. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-
smear technique in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo.
1972;14(6):397–400.
22. Lamberton PH, Kabatereine NB, Oguttu DW, Fenwick A, Webster JP. Sensitivity
and specificity of multiple Kato-Katz thick smears and a circulating cathodic
antigen test for Schistosoma mansoni diagnosis pre- and post-repeated-
praziquantel treatment. PLoS Negl Trop Dis. 2014;8(9):e3139.
23. van Dam GJ, Wichers JH, Ferreira TM, Ghati D, van Amerongen A, Deelder
AM. Diagnosis of schistosomiasis by reagent strip test for detection of
circulating cathodic antigen. J Clin Microbiol. 2004;42(12):5458–61.
24. Colley DG, Binder S, Campbell C, King CH, Tchuem Tchuenté LA, N’Goran
EK, et al. A five-country evaluation of a point-of-care circulating cathodic
antigen urine assay for the prevalence of Schistosoma mansoni. Am J Trop
Med Hyg. 2013;88(3):426–32.
25. Klager S, Whitworth JA, Post RJ, Chavasse DC, Downham MD. How long do
the effects of ivermectin on adult Onchocerca volvulus persist? Trop Med
Parasitol. 1993;44(4):305–10.
26. Kim JS, Oh DS, Ahn KS, Shin SS. Effects of kimchi extract and temperature
on embryostasis of Ascaris suum eggs. Korean J Parasitol. 2012;50(1):83–7.
27. Fallon PG, Doenhoff MJ. Drug-resistant schistosomiasis: resistance to
praziquantel and oxamniquine induced in Schistosoma mansoni in mice is
drug specific. Am J Trop Med Hyg. 1994;51(1):83–8.
28. Couto FF, Coelho PM, Araujo N, Kusel JR, Katz N, Jannotti-Passos LK, et al.
Schistosoma mansoni: a method for inducing resistance to praziquantel
using infected Biomphalaria glabrata snails. Mem Inst Oswaldo Cruz. 2011;
106(2):153–7.
29. Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, Wynn
NB, et al. Reduced susceptibility to praziquantel among naturally occurring
Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis. 2009;3(8):e504.
30. Lamberton PHL, Hogan SC, Kabatereine NB, Fenwick A, Webster JP. In
vitro praziquantel test capable of detecting reduced in vivo efficacy in
Schistosoma mansoni human infections. Am J Trop Med Hyg. 2010;
83(6):1340–7.
31. Danso-Appiah A, De Vlas SJ. Interpreting low praziquantel cure rates of
Schistosoma mansoni infections in Senegal. Trends Parasitol. 2002;18(3):125–9.
32. Wang W, Wang L, Liang YS. Susceptibility or resistance of praziquantel in
human schistosomiasis: a review. Parasitol Res. 2012;111(5):1871–7.
33. Wijngaarden PJ, van den Bosch F, Jeger MJ, Hoekstra RF. Adaptation to the
cost of resistance: a model of compensation, recombination, and selection
in a haploid organism. Proc Biol Sci R Soc. 2005;272(1558):85–9.
34. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to
reverse resistance? Nat Rev Microbiol. 2010;8(4):260–71.
35. Leathwick DM. Managing anthelmintic resistance – parasite fitness, drug use
strategy and the potential for reversion towards susceptibility. Vet Parasitol.
2013;198(1):145–53.
36. Webster JP, Woolhouse ME. Cost of resistance: relationship between
reduced fertility and increased resistance in a snail-schistosome host-
parasite system. Proc R Soc Lond B Biol Sci. 1999;266:391–6.
37. Blair L, Webster JP. Host reproductive fitness: the influence of increasing
parasite pressure in a Biomphalaria glabrata/Schistosoma mansoni system.
Invertebr Reprod Dev. 2002;41:1–3.
Lamberton et al. Infectious Diseases of Poverty  (2017) 6:110 Page 10 of 11
38. Davies CM, Fairbrother E, Webster JP. Mixed strain schistosome
infections of snails and the evolution of parasite virulence. Parasitology.
2002;124(Pt 1):31–8.
39. Davies CM, Webster JP, Woolhouse ME. Trade-offs in the evolution of
virulence in an indirectly transmitted macroparasite. Proc R Soc Lond B Biol
Sci. 2001;268(1464):251–7.
40. Webster JP, Gower CM, Blair L. Do hosts and parasites coevolve? Empirical
support from the Schistosoma system. Am Nat. 2004;164:S33–51.
41. Blair L, Webster JP. Dose-dependent schistosome-induced mortality and
morbidity risk elevates host reproductive effort. J Evol Biol. 2007;20(1):54–61.
42. Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF, Bennett JL.
Characterization of isolates of Schistosoma mansoni from Egyptian
villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg.
1996;55(2):214–8.
43. Cioli D, Botros SS, Wheatcroft-Francklow K, Mbaye A, Southgate V, Tchuem
Tchuente LA, et al. Determination of ED50 values for praziquantel in
praziquantel-resistant and -susceptible Schistosoma mansoni isolates. Int J
Parasitol. 2004;34(8):979–87.
44. Purnell RE. Host-parasite relationships in schistosomiasis. II. The effects of
age and sex on the infection of mice and hamsters with cercariae of
Schistosoma mansoni and of hamsters with cercariae of Schistosoma
haematobium. Ann Trop Med Parasitol. 1966;60(1):94–9.
45. Théron A, Pages JR, Rognon A. Schistosoma mansoni: distribution patterns of
miracidia among Biomphalaria glabrata snail as related to host susceptibility
and sporocyst regulatory processes. Exp Parasitol. 1997;85(1):1–9.
46. Southgate VR, Tchuente LA, Theron A, Jourdane J, Ly A, Moncrieff CB, et al.
Compatibility of Schistosoma mansoni Cameroon and Biomphalaria pfeifferi
Senegal. Parasitology. 2000;121(Pt 5):501–5.
47. Webster JP. Compatibility and sex in a snail-schistosome system.
Parasitology. 2001;122(Pt 4):423–32.
48. Olivier L, Haskins WT. The effects of low concentrations of sodium
pentachlorophenate on the fecundity and egg viability of Australorbis
glabratus. Am J Trop Med Hyg. 1960;9:199–205.
49. Paraense WL, Correa LR. Variation in susceptibility of populations of
Australorbis glabratus to a strain of Schistosoma mansoni. Rev Inst Med Trop
Sao Paulo. 1963;5:15–22.
50. Richards CS. Genetics of a molluscan vector of Schistosomiasis. Nature.
1970;227(5260):806–10.
51. Loker ES. A comparative study of the life-histories of mammalian
schistosomes. Parasitology. 1983;87(Pt 2):343–69.
52. Smithers SR, Terry RJ. The infection of laboratory hosts with cercariae of
Schistosoma mansoni and the recovery of the adult worms. Parasitology.
1965;55(4):695–700.
53. Zanotti-Magalhaes EM, Magalhaes LA, de Carvalho JF. Relationship between
the pathogenicity of Schistosoma mansoni in mice and the susceptibility of
the vector mollusk. III. Mortality, body and viscera weight. Rev Saude
Publica. 1995;29(4):265–70.
54. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models
using lme4. J Stat Softw. 2015;67(1):1–48.
55. WHO. Assessing the efficacy of anthelminthic drugs against schistosomiasis
and soil-transmitted helminths. Geneva: World Health Organization; 2013.
http://apps.who.int/iris/bitstream/10665/79019/1/9789241564557_eng.pdf.
Accessed 30 Mar 2017
56. Olliaro PL, Vaillant M, Diawara A, Coulibaly JT, Garba A, Keiser J, et al.
Toward measuring Schistosoma response to praziquantel treatment
with appropriate descriptors of egg excretion. PLoS Negl Trop Dis.
2015;9(6):e0003821.
57. Walker M, Mabud TS, Olliaro PL, Coulibaly JT, King CH, Raso G, et al. New
approaches to measuring anthelminthic drug efficacy: parasitological
responses of childhood schistosome infections to treatment with
praziquantel. Parasit Vectors. 2016;9:41.
58. Glinz D, Silue KD, Knopp S, Lohourignon LK, Yao KP, Steinmann P, et al.
Comparing diagnostic accuracy of Kato-Katz, Koga agar plate, ether-
concentration, and FLOTAC for Schistosoma mansoni and soil-transmitted
helminths. PLoS Negl Trop Dis. 2010;4(7):e754.
59. Gentile R, Goncalves MM, da Costa Neto SF, da Costa MM, Peralta RH,
Peralta JM. Evaluation of immunological, parasitological and molecular
methods for the diagnosis of Schistosoma mansoni infection before and
after chemotherapy treatment with praziquantel in experimentally infected
Nectomys squamipes. Vet Parasitol. 2011;180(3–4):243–9.
60. Campbell WC, Cuckler AC. Inhibition of egg production of Schistosoma
mansoni in mice treated with nicarbazin. J Parasitol. 1967;53(5):977–80.
61. Greenberg RM. Are Ca2+ channels targets of praziquantel action? Int J
Parasitol. 2005;35(1):1–9.
62. Liang YS, Coles GC, Doenhoff MJ, Southgate VR. In vitro responses of
praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel.
Int J Parasitol. 2001;31(11):1227–35.
63. Xiao SH, Wang CY, Jiao PY, Yu YG, Yuan XJ. Effect of praziquantel on
glycogen content and [1-14C] glucose uptake in Schistosoma japonicum
(author’s translation). Zhongguo Yao Li Xue Bao. 1981;2(3):204–11.
64. Andrews P, Thomas H, Pohlke R, Seubert J. Praziquantel. Med Res Rev. 1983;
3(2):147–200.
65. Coeli R, Baba EH, Araujo N, Coelho PM, Oliveira G. Praziquantel treatment
decreases Schistosoma mansoni genetic diversity in experimental infections.
PLoS Negl Trop Dis. 2013;7(12):e2596.
66. Popiel I. The reproductive biology of schistosomes. Parasitol Today. 1986;
2(1):10–5.
67. Pica-Mattoccia L, Moroni R, Tchuem Tchuente LA, Southgate VR, Cioli D.
Changes of mate occur in Schistosoma mansoni. Parasitology. 2000;120(Pt
5):495–500.
68. William S, Sabra A, Ramzy F, Mousa M, Demerdash Z, Bennett JL, et al.
Stability and reproductive fitness of Schistosoma mansoni isolates with
decreased sensitivity to praziquantel. Int J Parasitol. 2001;31(10):1093–100.
69. Gower CM, Shrivastava J, Lamberton PHL, Rollinson D, Webster BL, Emery A,
et al. Development and application of an ethically and epidemiologically
advantageous assay for the multi-locus microsatellite analysis of
Schistosoma mansoni. Parasitology. 2007;134(4):523–36.
70. Rollinson D, Johnston DA. Schistosomiasis: a persistent parasitic disease.
Interdiscip Sci Rev. 1996;21:140–54.
71. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet.
2006;368(9541):1106–18.
72. Saoud MF. The infectivity and pathogenicity of geographical strains of
Schistosoma mansoni. Trans R Soc Trop Med Hyg. 1966;60(5):585–600.
73. Brindley PJ, Sher A. The chemotherapeutic effect of praziquantel against
Schistosoma mansoni is dependent on host antibody response. J Immunol.
1987;139(1):215–20.
74. Brindley PJ, Strand M, Norden AP, Sher A. Role of host antibody in the
chemotherapeutic action of praziquantel against Schistosoma mansoni:
identification of target antigens. Mol Biochem Parasitol. 1989;34(2):99–108.
75. Brindley PJ, Sher A. Immunological involvement in the efficacy of
praziquantel. Exp Parasitol. 1990;71(2):245–8.
76. Doehring-Schwerdtfeger E, Abdel-Rahim IM, Kardorff R, Kaiser C, Franke D,
Schlake J, et al. Ultrasonographical investigation of periportal fibrosis in
children with Schistosoma mansoni infection: reversibility of morbidity
twenty-three months after treatment with praziquantel. Am J Trop Med
Hyg. 1992;46(4):409–15.
77. Mohamed-Ali Q, Doehring-Schwerdtfeger E, Abdel-Rahim IM, Schlake J,
Kardorff R, Franke D, et al. Ultrasonographical investigation of periportal
fibrosis in children with Schistosoma mansoni infection: reversibility of
morbidity seven months after treatment with praziquantel. Am J Trop Med
Hyg. 1991;44(4):444–51.
78. Wiest PM. The epidemiology of morbidity of schistosomiasis. Parasitol
Today. 1996;12(6):215–20.
79. Webster JP, Davies CM. Coevolution and compatibility in the snail-
schistosome system. Parasitology. 2001;123:S41–56.
80. Gower CM, Webster JP. Fitness of indirectly transmitted pathogens: restraint
and constraint. Evol Int J Org Evol. 2004;58(6):1178–84.
81. Bayne CJ, Loker ES: Survival within the snail host. In: The biology of
Schistosomes: from genes to latrines (Ed. by Rollinson, D. & Simpson, A. J.),
pp. 321-346. San Diego: Academic Press Ltd. In.; 1987.
82. Sorensen RE, Minchella DJ. Snail-trematode life history interactions: past
trends and future directions. Parasitology. 2001;123:S3–18.
Lamberton et al. Infectious Diseases of Poverty  (2017) 6:110 Page 11 of 11
